The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.

Trial Profile

The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tumour necrosis factor alpha inhibitors
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms DREAM-TIME
  • Most Recent Events

    • 30 Oct 2013 Preliminary results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 16 Feb 2012 Additional lead trial centre identified as reported by Netherlands Trial Register.
    • 16 Feb 2012 Planned End Date changed from 31 Dec 2011 to 31 Mar 2013 as reported by Netherlands Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top